Alto Neuroscience (ANRO) Enterprise Value (2023 - 2026)

Alto Neuroscience has disclosed Enterprise Value across 4 years of filings, most recently posting -$263.8 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$263.8 million, down 64.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$263.8 million (down 64.08% YoY), and the FY2025 annual result was -$176.5 million, down 4.93% from the prior year.
• Enterprise Value came in at -$263.8 million for Q1 2026 at Alto Neuroscience, down from -$176.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$82.5 million in Q4 2023 to a low of -$263.8 million in Q1 2026.
• The 4-year median for Enterprise Value is -$172.3 million (2024), against an average of -$171.8 million.
• Across the five-year window, Enterprise Value tumbled 103.88% in 2024 and climbed 24.15% in 2025, its largest moves.
• Alto Neuroscience's Enterprise Value stood at -$82.5 million in 2023, then tumbled by 103.88% to -$168.2 million in 2024, then dropped by 4.93% to -$176.5 million in 2025, then plunged by 49.45% to -$263.8 million in 2026.
• The last three Enterprise Value figures came in at -$263.8 million (Q1 2026), -$176.5 million (Q4 2025), and -$137.8 million (Q3 2025), per Business Quant data.